Abstract 1675P
Background
Adjuvant hormonal therapy (AHT) is integral to breast cancer management but often severely impacts the quality of life (QoL), especially concerning sexual functioning and psychological well-being. This study evaluates the effects of AHT on the sexual and global QoL of young breast cancer survivors.
Methods
This cross-sectional study was conducted at two cancer centers within Cairo, Egypt, involving 644 young breast cancer patients. The European Organization for Research and Treatment of Cancer EORTC QLQ - BR45 questionnaire was employed to assess the impact of AHT on sexual and global QoL. Data analysis encompassed demographic factors, treatment regimens, duration of therapy, functional and symptomatic scales of the questionnaire.
Results
The participants' median age was 41 years (range: 25-45), the primary AHT consisted of Tamoxifen + LHRH analogues (55.4%). there was a notable decrease in sexual enjoyment, with 50.7% of participants reporting no sexual activity in the past month. Among those who were sexually active, only 7.1% reported high enjoyment post-treatment compared to 31.5% pre-treatment. Additionally, 48.1% of patients experienced a complete lack of sexual desire post-treatment, while 38% expressed a significant need for psychological support. Analysis of the EORTC QLQ - BR45 questionnaire revealed Sexual Enjoyment Score: 52.9, Body image score 59.3, and Endocrine side effect score 49.4.
Conclusions
The findings reveal a profound impact of AHT on both the sexual and overall QoL among young breast cancer patients. The significant decline in sexual enjoyment and desire, coupled with a substantial need for psychological support, underscores the necessity for integrated care strategies that address the comprehensive health challenges faced by young breast cancer survivors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1699P - Impact of Latino ethnicity on the gut microbiome and response to immune checkpoint inhibition (ICI) with CBM588 in patients (pts) with metastatic renal cell cancer (mRCC)
Presenter: Regina Barragan-Carrillo
Session: Poster session 11
1700P - Impact of sarcomatoid (S) and rhabdoid (R) components (comp.) on the efficacy of nivolumab (N) +/- ipilimumab (I) in the first-line (L1) treatment of metastatic clear cell renal cell carcinoma (mRCC) in the randomized phase II BIONIKK trial
Presenter: Yann-Alexandre Vano
Session: Poster session 11
1701P - NEOTAX: A phase II trial of neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus
Presenter: Liangyou Gu
Session: Poster session 11
1702P - Updated results of phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with divergent histologies (RCCdh)
Presenter: Bradley McGregor
Session: Poster session 11
1703P - Updated overall survival in patients with prior checkpoint inhibitor (CPI) therapy in the phase III TIVO-3 study
Presenter: Miguel Zugman
Session: Poster session 11
1704P - Potential surrogate endpoints for overall survival (OS) in immunotherapy (IO)-treated metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study
Presenter: Renee Saliby
Session: Poster session 11
1705P - Association between baseline radiological tumor burden (BRTB) and outcomes in metastatic clear cell renal cell carcinoma (mccRCC) treated with first line (1L) immunotherapy (IO)-based regimens
Presenter: Rashad Nawfal
Session: Poster session 11
1707P - A plasma proteomic based algorithm is associated with prognosis in renal cell carcinoma
Presenter: Eddy Saad
Session: Poster session 11
1708P - The clinical value of tumor-informed minimal residual disease detection in renal cell carcinoma
Presenter: linhui wang
Session: Poster session 11